Industry Medical Devices Revenue 329.5 million USD (2016) | Founded 1981 | |
 | ||
Traded as NASDAQ: ABMD
S&P 400 Component Key people Michael R. Minogue, CEO, President & Chairman of the board
Mr. Michael Tomsicek, CFO
Dr. David Weber, COO
Dr. Seth Bilazarian, CMO Products Impella
AbioCor
iPulse
IAB
AB5000
BVS 5000 Operating income Stock price ABMD (NASDAQ) US$ 117.94 0.00 (0.00%)27 Feb, 4:00 PM GMT-5 - Disclaimer CEO Michael R. Minogue (6 Apr 2004–) Headquarters Danvers, Massachusetts, United States Subsidiaries Abiomed Athlone Ltd, Abiomed SARL Profiles | ||
Abiomed impella 2 5 heart pump demo
Abiomed (NASDAQ: ABMD) is a manufacturer of medical implant devices, including the AbioCor artificial heart and Impella. It is headquartered in Danvers, Massachusetts and has an additional office in Aachen, Germany. It has 800 employees worldwide. Michael R. Minogue joined Abiomed in 2004, and serves as CEO, Chairman and President.
Contents
For fiscal year 2016, Abiomed reported $329.5 million in revenue, $65.1 million in operating income, $38.1 million in net income, $423 million in total assets, and $369 million in equity.
Impella 5 0
History
Abiomed was founded in Danvers by David M. Lederman in 1981 as Applied Medical Corporation, and began working on the development of an artificial heart. Funded by federal research grants, Lederman partnered with The Texas Heart Institute to develop the AbioCor, implanting the first artificial heart into a Kentucky man in July 2001. Fourteen of the AbioCor devices were implanted, during clinical trials from 2001 to 2004, with the longest-living recipient surviving 512 days. The AbioCor won FDA approval in 2006 for patients who are near death and do not qualify for a heart transplant.
In 2004, Michael R. Minogue became president and CEO of Abiomed. In 2005, Abiomed purchased ventricular assist device company Impella CardioSystems AG of Aachen, Germany, maker of the Impella heart pump, developed by Dr. Thorsten Siess, who is now the Chief Technology Officer at Abiomed.
Since 2005, Impella heart devices have received a series of FDA approvals, helping more than 37,000 people.
In 2007, the Impella 2.5 heart pump was among 35 healthcare products to receive a 2007 Medical Design Excellence Award.
Minogue helped found the Medical Technology Veterans Program (MVP), a career training and mentorship initiative designed to help veterans entering the civilian workforce transition into jobs in the medical device and life sciences industries. He currently serves as chairman of the program.